Preoperative details of patients.
Significant atherosclerotic disease affecting also the carotid artery system is encountered in a substantial number of patients undergoing coronary artery bypass grafting (CABG) . The optimal surgical management to prevent stroke and cardiac events in this subset of patients remains unclear [2-5]. Among patients undergoing carotid endoarterectomy (CEA) procedure in the Veterans Affair Cooperative Study and in the Asymptomatic Carotid Atherosclerosis Study, respectively 20% and 49% of deaths were related to cardiac causes . Similarly, the incidence of perioperative stroke in patients undergoing CABG is high in those affected by concomitant significant carotid disease [2-4]. The combined surgical approach is associated with an increased risk for mortality and morbidity . In the staged surgical approach which addresses the carotid artery lesion with carotid endoarterectomy first, followed several days to several weeks by CABG, incidence of perioperative stroke during CABG is reduced.However, the risk of myocardial infarction (MI) during the CEA procedure and in the period preceding CABG remains high (6%) . Carotid artery stenting (CAS) using cerebral protection devices is rapidly evolving as an alternative to carotid endoarterectomy , mainly for patients with severe carotid artery stenosis at high surgical risk , such as patients with coronary artery disease. A staged CAS-CABG approach has been recently proposed, but the need of a dual anti-platelet aggregation therapy lasting 3-4 weeks after stenting may represent a limitation for CABG .
2. Clinical experience
In our Institution in 2005 we introduced a new therapeutic strategy consisting of a simultaneous hybrid revascularization by CAS, immediately followed by CABG and cases have been colleted in the SHARP study (“
As compared to the combined or staged surgical strategy currently adopted, the new hybrid approach CAS-CABG can reduce the incidence of serious perioperative adverse events and minimize surgical trauma. Surgical time and surgical trauma are shorter and less extensive as compared to combined CEA and CABG. Risk of MI is expected to be reduced, by shortening the interval between the two procedures [10, 11].
CAS procedures were performed under local anaesthesia through a percutaneous transfemoral access with the use of stents and protection devices. An introducer sheath was positioned in the femoral artery, and heparin (1 mg /kg) was administered intra-arterially as a bolus. Then a guiding catheter was placed in the common carotid artery, proximally to the bifurcation. A distal filter protection was used in all patients. At the end of the procedure, patients were transferred directly to the operating room; CABG procedure was performed by means of normothermic cardiopulmonary bypass in the majority patients; in few cases off-pump CABG procedure was performed according with the choice of surgeon and comorbidity of patient.
2.1. Periprocedural pharmacological protocol
Aspirin 100 mg daily was started at least 2 days before CAS and daily after combined procedure was performed. Heparin was administered 1 mg /Kg as a bolus intra-arterially immediately before the stent implantation procedure and in the operating room before the cardiopulmonary bypass 2 mg/Kg as a bolus. Activated clotting time was checked every 30 minutes and was constantly maintained ≥ 250 sec. until the CABG procedure and ≥480 seconds until the end of the cardiopulmonary bypass. Tranexamic acid 2 g in bolus was administered as an antifibrinolytic agent over 20 minutes before sternotomy and then as endovenous infusion (0.5 g/h) until the patient was admitted to the postoperative intensive care unit in most of cases. Clopidogrel, 300 mg as a loading dose, followed by 75 mg per day for 1 month was started in the intensive care unit via a nasogastric tube 6 hours after the end of CABG surgery, providing that surgical bleeding from the thoracic drains had either stopped, or when it was less than 50 mL/hr for 3 consecutive hours from the sixth postoperative hour on (Figure 2).
The primary end points analyzed were the incidence of stroke, MI or death at 30 days after CAS-CABG and at a mid-term follow-up.
2.2. In-hospital and follow-up results
One-hundred and forty eight consecutive patients between January 2005 and November 2011 underwent CAS-CABG treatment. Mean age of patients was 68±8 years, means EuroSCORE 8.6±2.5; 22 patients (14.8%) were affected by symptomatic carotid disease; 67 (45%) had bilateral carotid stenosis. Left internal mammary artery was used as graft to the left anterior descending artery in all patients, bilateral mammary artery in 20 cases (13.5%). (Table 1).
|Number of patients||148|
|Age - years ||68±8|
|Male - n.||118 (79)|
|CCS pre-op - mean ||2.7±1|
|CCS class III/IV ||93 (63)|
|Instable Angina- n. (%)||34 (23)|
|NYHA – mean ||2.2±1|
|Bilateral carotid stenosis- n. (%)||67 (45)|
|Previous Stroke o TIA - n. (%)||22 (14,8)|
|Surgical Risk||8.6 ± 2.5|
|Doppler velocity of internal carotid artery. - mean ||325 ±40cm/sec|
|Re-exploration for bleeding||2.0%|
|Stroke, MI or death within 48 months||6.1%|
In the first one hundred patients we report a mean follow-up of 40±25 months, 97% complete. In these patients we found at the end of follow-up 9 deaths whit a cumulative survival rate of 89%; furthermore we observed a very low mortality rate for cardiac late death (97±2%) and an high rate of freedom from fatal stroke (we registered just one case of fatal stroke during follow-up) (98±2%), MI (96±3%), and cerebrovascular events (90±6%). (Figure 3-6)
Internal carotid artery systolic blood flow during follow-up, showed significant improvement as compared to preoperative mean value. (67±10 cm/sec vs. 325±40 cm/sec,
Neurological complications are relatively common after CABG, especially in high-risk patients. Carotid artery disease is significantly associated with a type I adverse neurological outcome (i.e., death due to stroke or hypoxic encephalopathy, nonfatal stroke, TIA, stupor, or coma at the time of discharge). Significant carotid artery stenoses are associated with up to 30% of early postoperative strokes following CABG. Preventing stroke and cardiovascular events after CABG is an important and complex issue. Concomitant carotid artery disease might be a major factor contributing to the occurrence of postoperative stroke. Moreover, carotid artery disease might be a marker of diffuse atherosclerosis, affecting also aortic arch, arch vessels, and intracranial vessels. In this high risk population, a simplified operative management like hybrid revascularization by CAS and CABG can minimize the negative impact of diffuse atherosclerotic disease. In fact, our findings indicate that, in patients with combined carotid artery disease and coronary artery disease, the proposed hybrid approach is a feasible therapeutic option with good immediate and short-term clinical results. The recently reported incidence of perioperative stroke and mortality following CEA and CABG is not negligible, ranging between 8.3% to 10.3% . According to these results, in a previous series of 100 consecutive patients undergoing combined surgical revascularization at our Institution between 1991 and 2002, the 30-day mortality and stroke rate was 10% and 1.1%, respectively, with a mortality rate of 14.5% when the standard EuroSCORE was ≥ 6, and 3.4% when it was lower than 6. These high-risk patients could be treated by an alternative strategy such as the hybrid approach proposed in this study. As compared with combined surgical revascularization, the hybrid strategy requires a shorter surgical time and less extensive surgical trauma, thus reducing cofactors known to increase morbidity and mortality.In particular, in high-risk patients for CEA, mainly due to severe CAD, the SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) trial showed that CAS was safer than carotid endarterectomy, because it had a lower postprocedural risk of myocardial infarction at 30 days as compared with surgery. This is likely to be the case mainly in patients with elevated surgical risk, such as the patients involved in the SHARP study. In particular, when the standard EuroSCORE is 8, as it is in our study, the surgical mortality rate might be greater than 10-12%. In this high-risk subset of patients, specific surgical complications are also increased up to 55% . When both internal carotid arteries have significant stenosis, the risk of stroke after cardiac surgery is particularly high (25%). With the percutaneous hybrid approach, in our study the stroke rate was only 1.3%, considering that 45% of our patients had bilateral internal carotid artery disease. Potential adjunctive advantage of the simultaneous hybrid approach as compared with a combined surgical approach is that during the CAS procedure the patient is awake and the neurological outcome will be known instantly rather than after the patient emerges from general anaesthesia. Another most important finding of our study was the absence of periprocedural rate of MI. By observing the proposed protocol, the risk of MI, especially during carotid surgery or in the time elapsing between the two procedures (CEA or CAS and CABG after 3-4 weeks from carotid procedure), is virtually eliminated. In the two-stage procedure, the rate of MI when the patient is waiting for CABG after carotid artery procedure is about 5-6%. Finally our study also demonstrated safety of the pharmacological protocol and the timing of antiplatelet administration proposed: the bleeding rate after surgical intervention was low.
The proposed hybrid approach conferred an operative mortality rate comparable to that of isolated CABG.
In conclusions, the new hybrid approach is aiming to reduce risk of myocardial infarction, of bleeding after CABG and risk of death and major cerebrovascular complications. Reduced mortality and morbidity are expected to reduce also in-hospital stay and costs. Therefore, in patients with combined carotid artery and coronary artery disease at higher surgical risk, the proposed hybrid approach seems to be a possible, advantageous and safe alternative therapeutic strategy.
At a mid-term period, a high rate of event-free survival and freedom from cerebrovascular events can be expected.